(Z)-5-(4-methoxybenzylidene) thiazolidine-2, 4-dione ameliorates the adjuvant-induced arthritis via inhibiting the migration of macrophage and down-regulating the cytokine mRNA expression

International Immunopharmacology

Volumn 10, Issue 11, 2010, Pages 1456-1462

  Ma, Yinghua ^a   Wang, Xianhuo ^a   Wu, Xiaohua ^a   Wei, Xin ^a   Ma, Liang ^a   Zheng, Hao ^a   Qi, Baowen ^a   Zhu, Wei ^a   Luo, Youfu ^a   Wei, Yuquan ^a   Chen, Lijuan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

(Z) 5 (4 methoxybenzylidene) thiazolidine 2; 4 dione; IL 1 ; IL 6; Macrophages; Rheumatoid arthritis; TNF

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 (4 METHOXYBENZYLIDENE)THIAZOLIDINE 2,4 DIONE; CD68 ANTIGEN; CYTOKINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; NITRIC OXIDE; SKLB 010; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG MECHANISM; FEMALE; GENE EXPRESSION REGULATION; MACROPHAGE MIGRATION; MOUSE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ARTHRITIS, EXPERIMENTAL; CELL LINE; CELL MIGRATION INHIBITION; CYTOKINES; DOWN-REGULATION; FEMALE; INTERLEUKIN-1BETA; INTERLEUKIN-6; MACROPHAGES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; RATS; SEVERITY OF ILLNESS INDEX; SYNOVIAL MEMBRANE; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77958150988     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.08.022     Document Type: Article

References (33)

1. Borchers A.T., Keen C.L., Cheema G.S., Gershwin M.E. The use of methotrexate in rheumatoid arthritis. Semin Arthritis Rheum 2004, 34:465-483.
2. Lee D.M., Weinblatt M.E. Rheumatoid arthritis. Lancet 2001, 358:903-911.
3. Kim H.L., Cho Y.S., Choi H., Chun Y.S., Lee Z.H., Park J.W. Hypoxia-inducible factor1 alpha is deregulated by the serum of rats with adjuvant-induced arthritis. Biochem Bioph Res Commun 2009, 378:123-128.
4. Cavaillon J.M. Cytokines and macrophages. Biomed Pharmacother 1994, 48:445-453.
5. Mythilypriya R., Shanthi P., Sachdanandam P. Ameliorating effect of Kalpaamruthaa, a Siddha preparation in adjuvant induced arthritis in rats with reference to changes in proinflammatory cytokines and acute phase proteins. Chem-Biol Interact 2009, 179:335-343.
6. Szekanecz Z., Halloran M.M., Volin M.V., Woods J.M., Strieter R.M., Haines G.K., et al. Temporal expression of inflammatory cytokines and chemokines in rat adjuvant-induced arthritis. Arth Rheum 2000, 43:1266-1277.
7. Joosten L.A.B., Berg W.B. IL-1 in chronic arthritis, lessons from animal models. Drug Discov Today 2006, 3:169-175.
8. Fan Z., Bau B., Yang H., Aigner T. IL-17β induction of IL-6 and LIF in normal articular human chondrocytes involves the ERK, p38 and NF-κB signaling pathways. Cytokine 2004, 28:17-24.
9. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002, 2:364-371.
10. Liacini A., Sylvester J., Wenqing Li., Huang W., Dehnade F., Ahmad M., et al. Induction of matrix metalloproteinase-13 gene expression by TNF-alpha is mediated by MAP kinases, AP-1, and NF-kappa B transcription factors in articular chondrocytes. Exp Cell Res 2003, 288:208-217.
11. Ghivizzani S.C., Lechman E.R., Kang R., Tio C., Kolls J., Evans C.H., et al. Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc Natl Acad Sci USA 1998, 95:4613-4618.
12. Maini R.N., Taylor P.C. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 2000, 51:207-229.
13. Scheinecker C., Redlich K., Smolen J.S. Cytokines as therapeutic targets: advances and limitations. Immunity 2008, 28:440-444.
14. Stamp L.K., James M.J., Cleland L.G. Diet and rheumatoid arthritis: a review of the literature. Semin Arthritis Rheum 2005, 35:77-94.
15. Shiojiri T., Wada K., Nakajima A., Katayama K., Shibuya A., Kudo C., et al. PPAR gamma ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-induced rheumatoid arthritis mice. Eur J Pharmacol 2002, 448:231-238.
16. Hamnvik O.P., McMahon G.T. Balancing risk and benefit with oral hypoglycemic drugs. Mt Sinai J Med 2009, 76:234-243.
17. Luo YF, MaL, Zheng H, Chen LJ, Li R, He CM, et al. Discovery of (Z)-5-(4-Methoxybenzylidene)thiazolidine-2, 4-dione, a readily available and orally active glitazone for the treatment of concanavalin A-induced acute liver injury of BALB/c mice. J Med Chem. 2010;53:273-81.
18. Schett G., Middleton S., Bolon B., Stolina M., Brown H., Zhu L., et al. Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. Arth Rheum 2005, 52:1604-1611.
19. Williams A.S., Topley N., Dojcinov S., Richards P.J., Williams B.D. Amelioration of rat antigen-induced arthritis by liposomally conjugated methotrexate is accompanied by down-regulation of cytokine mRNA expression. Rheumatology 2001, 40:375-383.
20. Weigert A., Weis N., Brune B. Regulation of macrophage function by sphingosine-1-phosphate. Immunobiology 2009, 214:748-760.
21. Paulos C.M., Turk M.J., Breur G.J., Low P.S. Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Delivery Rev 2004, 56:1205-1217.
22. Suzuki Y., Inoue K., Chiba J., Inoue Y., Kanbe K. Histological analysis of synovium by treatment of etanercept for rheumatoid arthritis. Int J Rheumatic Dis 2009, 12:7-13.
23. Barrera P., Blom A., Van Lent P.L., Van Bloois L., Beijnen J.H., Van Rooijen N., et al. Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum 2000, 43:1951-1959.
24. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Davis D., Macfarlane J.D., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arth Rheum 1998, 41:1552-1563.
25. Caporali R., Pallavicini F.B., Filippini M., Gorla R., Marchesoni A., Favalli E.G., et al. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun Rev 2009, 8:274-280.
26. Zhou H., Wong Y.F., Wang J., Cai X., Liu L. Sinomenine ameliorates arthritis via MMPs, TIMPs, and cytokines in rats. Biochem Bioph Res Commun 2008, 376:352-357.
27. Dayer J.M. The saga of the discovery of IL-1 and TNF and their specific inhibitors in the pathogenesis and treatment of rheumatoid arthritis. Joint Bone Spine 2002, 69:123-132.
28. Iwakura Y. Roles of IL-1 in the development of rheumatoid arthritis: consideration from mouse models. Cytokine Growth Factor Rev 2002, 13:341-355.
29. Hosaka K., Ryu J., Saitoh S., Ishii T., Kuroda K., Shimizu K. The combined effects of anti-TNFa antibody and IL-1 receptor antagonist in human rheumatoid arthritis synovial membrane. Cytokine 2005, 32:263-269.
30. Nishimoto N., Kishimoto T., Yoshizaki K. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 2000, 59:21-27.
31. Wendling D., Racadot E., Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 1993, 20:259-262.
32. Takagi N., Mihara M., Moriya Y., Nishimoto N., Yoshizaki K., Kishimoto T., et al. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arth Rheum 1998, 41:2117-2121.
33. Pan R., Dai Y., Gao X.H., Xia Y.F. Scopolin isolated from Erycibe obtusifolia Benth stems suppresses adjuvant-induced rat arthritis by inhibiting inflammation and angiogenesis. Int Immunopharmacol 2009, 9:859-869.